SREBP-1 and SCAP expression are strongly associated with disease progression and a poor prognosis in NSCLC, making them reliable biomarkers and potential molecular targets for the treatment of lung adenocarcinoma. This evidence concerns the gene SREBF1 and lung adenocarcinoma.